Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting
– Prof. Steinman's groundbreaking research linking Epstein-Barr virus to multiple sclerosis named a runner-up for the 2022 Science Magazine Breakthrough of the Year –
— 施坦曼教授的突破性研究將愛潑斯坦-巴爾病毒與多發性硬化症聯繫起來，榮獲 2022 年科學雜誌年度突破獎亞軍 —
PALO ALTO, Calif. and MIAMI, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced that Prof. Lawrence Steinman, Pasithea's Chairman and National Academy of Sciences Professor, will deliver the keynote address at the American Association for the Advancement of Science (AAAS) Annual Meeting, on March 4 from 11:30am-12:30pm ET, in Washington DC.
加州帕洛阿爾托和佛羅里達州邁阿密，2023 年 3 月 02 日（GLOBE NEWSIRE）-帕西亞治療股份有限公司（NASDAQ：KTTA）（「Pasithea」或「公司」），一家專注於發現，研究和開發中樞神經系統（CNS）疾病創新治療的生物技術公司，今天宣布，斯坦西亞學院主席和 Pasinthea 學院主席科學教授將在美國科學促進協會（AAAS）年會上發表主題演講，於美國東部時間 3 月 4 日上午 11:30 至下午 12:30 在華盛頓特區舉行。
AAAS is the world's largest general scientific society, with over 120,000 members, and is the publisher of the scientific journal Science. Prof. Steinman's research on the link between the Epstein-Barr virus and multiple sclerosis (MS) was a runner-up for the 2022 Science Magazine Breakthrough of the Year.
AAAS 是世界上最大的一般科學社會，擁有超過 12 萬名會員，並且是該科學期刊的出版商 科學。斯坦曼教授對愛潑斯坦-巴爾病毒與多發性硬化症（MS）之間聯繫的研究在 2022 年獲得亞軍 科學 雜誌年度突破。
"I'm honored to be asked to address such an important assembly of scientists and to share insight on this critical work with peers," commented Dr. Steinman. "Recognition of the work by Science is thrilling because of the attention it brings to our effort to fight MS."
斯坦曼博士評論說：「我很榮幸能夠解決如此重要的科學家集會，並與同行分享對這項關鍵工作的見解。」「通過工作的認可 科學 令人興奮，因為它給我們的努力與 MS 作鬥爭帶來的關注。」
About PAS-002
關於 PAS-002
The Company's PAS-002 discovery program aims to develop a proprietary engineered DNA plasmid vaccine to tolerize the immune system to GlialCAM for the treatment of Multiple Sclerosis. GlialCAM, a CNS protein, found in the brain's white matter is attacked in MS. GlialCAM shares a component of its structure that mimics an identical component of Epstein-Barr virus nuclear antigen 1 (EBNA-1), which plays a critical role in triggering MS.
該公司的 PAS-002 發現計劃旨在開發專有的工程 DNA 質粒疫苗，以容忍 GlialCam 的免疫系統以治療多發性硬化症。GlialCam 是一種中樞神經系統蛋白質，在 GlialCam 女士中發現的中樞神經系統蛋白質在 GlialCam 女士中受到攻擊，其結構的一個組成部分模仿愛潑斯坦-巴爾病毒核抗原 1（EBNA-1）的相同成分，該組成部分在觸發 MS.
About Multiple Sclerosis
關於多發性硬化症
Multiple Sclerosis ("MS") is a chronic and potentially disabling autoimmune disease, and the most common neurodegenerative disease of the central nervous system in young adults. The pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord, with the immune system attacking the myelin sheath that normally protects nerve fibers in the brain, spinal cord, and optic nerve. There are now 2.8 million people worldwide who have MS, and every five minutes, someone, somewhere in the world is diagnosed with this disorder. While there is no way to predict with any certainty how an individual's disease will progress, four basic MS disease courses (also called types or phenotypes) have been defined: clinically isolated syndrome, relapsing remitting, secondary progressive and primary progressive. The most common affecting around 85 per cent of everyone diagnosed with MS is relapsing remitting MS (RRMS). It means that symptoms appear (a relapse), and then fade away, either partially or completely (remitting).
多發性硬化症（「MS」）是一種慢性和潛在的自身免疫性疾病，也是年輕人中樞神經系統中最常見的神經退行性疾病。MS 的病理標誌是在大腦和脊髓中形成脫髓鞘病變，免疫系統會攻擊通常保護大腦，脊髓和視神經中的神經纖維的髓鞘。現在全世界有 280 萬人患有 MS，每五分鐘一次，世界上某個地方的某個人被診斷出患有這種疾病。雖然沒有辦法確定地預測個人的疾病將如何進展，但已經定義了四個基本的 MS 疾病課程（也稱為類型或表型）：臨床孤立綜合徵，復發緩解，繼發漸進和初級漸進。最常見的影響大約 85 ％ 的每個人都被診斷為 MS 復發放 MS（RRMS）。這意味著症狀出現 (復發), 然後消失, 無論是部分或完全 (緩解).
About Pasithea Therapeutics Corp.
關於帕西亞治療公司
Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS), Neurofibromatosis type 1 (NF1) and Noonan syndrome.
Pasithea 治療是一家生物技術公司，主要專注於發現，研究和開發中樞神經系統（CNS）疾病的創新治療方法。Pasithea 擁有一支經驗豐富的神經科學和心理藥理學專家團隊，正在開發用於治療神經系統疾病的新分子實體，包括肌萎縮性側索硬化症（ALS）和多發性硬化症（MS），1 型神經纖維瘤（NF1）和努南綜合徵。
Forward Looking Statements
前瞻性陳述
This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
本新聞稿包含構成「前瞻性陳述」的陳述。前瞻性陳述受到許多條件的約束，其中許多條件超出了公司的控制範圍。雖然本公司認為這些前瞻性陳述是合理的，但不應對任何此類前瞻性陳述作出不當的依賴，而這些陳述是根據本新聞稿日期提供給本公司的資料而作出的。這些前瞻性陳述是根據目前的估計和假設而定，並受到各種風險和不確定性的影響，包括但不限於本公司向美國證券交易委員會（SEC）提交的文件中列出的風險和不確定性。因此，實際結果可能會有很大的不同。除非法律要求，否則公司不承擔任何義務，無論是由於新信息，未來事件還是其他原因而更新這些聲明。
Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
Email: tiago@pasithea.com
公司聯絡
蒂亞戈·雷斯·馬克斯博士
首席執行官
電郵地址:tiago@pasithea.com
譯文內容由第三人軟體翻譯。